Mineralys Therapeutics Unveils Pivotal Data at ACC.25
Portfolio | Mar 29, 2025 | Ysios Capital
Mineralys Therapeutics has presented late-breaking data from the Advance-HTN pivotal trial of its drug lorundrostat at the American College of Cardiology’s Annual Scientific Session & Expo (ACC.25). The results suggest that lorundrostat holds promise as a best-in-class treatment option for patients with uncontrolled or resistant hypertension. The data from Advance-HTN supports the drug's potential to address high-risk patients effectively. This impactful reveal underscores Ysios Capital's investment in innovative medical solutions.
Sectors
- Biotechnology
- Healthcare
Geography
- United States – The American College of Cardiology’s Annual Scientific Session & Expo takes place in the United States, where the pivotal data was presented.
Industry
- Biotechnology – The development of lorundrostat by Mineralys Therapeutics falls under biotechnology as it involves the application of biological systems to produce a medicinal treatment.
- Healthcare – The article deals with advancements in treating hypertension, a major health issue, situating it firmly within the healthcare sector.
Financials
- – No specific financial values are mentioned in the article.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Mineralys Therapeutics | Target Company | Company | A biotechnology company focused on developing treatments for resistant hypertension. |
| Ysios Capital | Private Equity Firm | Company | An investment firm backing innovative healthcare solutions. |